Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
C10AX13 - EvolocumabATC-DDD Version 2016. Source: WHO
C - Cardiovascular System
C10 - Lipid Modifying Agents

The DDDs are based on the treatment of hypercholesterolemia.

C10A - Lipid Modifying Agents, plain

Pantethine, which is also used in the treatment of hyperlipidemi, is classified as a vitamin in A11HA.

C10AX - Other Lipid Modifying Agents

This group comprises all cholesterol and triglyceride reducers, which cannot be classified in the preceding groups.
Sulodexide is classified in B01AB.

The DDD for evolocumab is based on dosing every second week.

C10AX13 - Evolocumab
2020 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home